This inventor holds 3 USPTO granted patents and 4 published patent applications and 2 EPO patents. Top assignees: University of Bern, Universitât Bern. Active years: 2019-2025.
Company Filing History:
Years Active: 2019-2025
Title: Carsten Riether: Innovator in Hematologic Malignancies
Introduction
Carsten Riether is a notable inventor based in Bern, Switzerland. He has made significant contributions to the field of hematologic malignancies through his innovative research and patented inventions. With a total of 3 patents, Riether's work focuses on developing therapeutic strategies for treating blood-related cancers.
Latest Patents
One of Riether's latest patents is titled "Ligands to light or its receptor LTßR for use in haematologic malignancies." This invention relates to a non-agonist ligand, particularly an antibody, that specifically binds to LIGHT or its receptor LTβR. This binding interrupts the interaction of LIGHT with LTβR, providing a potential treatment for hematologic malignancies. Another significant patent is "Anti-CD70 and BCR-ABL inhibitor combination therapy." This patent outlines methods and compositions for treating BCR-ABL1 related disorders, such as chronic myelogenous leukemia, using a therapeutic combination of a WNT signaling pathway inhibitor and a BCR-ABL1 tyrosine kinase inhibitor.
Career Highlights
Carsten Riether has worked at the University of Bern, where he has contributed to various research projects and advancements in the field of hematology. His work has been instrumental in developing new therapeutic approaches for treating blood cancers.
Collaborations
Riether has collaborated with notable colleagues, including Adrian Ochsenbein and Christian Schürch. These collaborations have further enhanced his research and contributed to the development of innovative treatments.
Conclusion
Carsten Riether's contributions to the field of hematologic malignancies through his patents and research collaborations highlight his role as a significant innovator. His work continues to pave the way for new therapeutic strategies in treating blood-related cancers.